Lupin settlement with resellers gets first approval in US generic drug antitrust case
MLex Summary: Lupin Pharmaceuticals’ $5.7 million settlement has been granted preliminary approval to resolve indirect resellers US price-fixing allegations over generic drugs.See attached file. ...To view the full article, register now.
Already a subscriber? Click here to view full article